Relief Therapeutics Holding AG (RLFTF)

[threebabiesbusy]

Thanks "mytoessmell" from yahoo RLF yahoo board

The significant clinical improvement seen in these 21 patients treated with intravenous RLF-100 (Aviptadil), is consistent with the finding that VIP not only blocks viral replication in the pulmonary epithelium but creates a “bystander effect” whereby nearby monocytes secrete soluble antiviral agents to further protect ATII cells, blocks cytokine storm, and improves oxygenation in a lung that is under attack by the SARS-CoV-2 virus. This highly specific role of VIP in the lung may be key to combating the lethal effects of SARS-CoV-2 infection. A randomized prospective trial is underway, which will attempt to demonstrate that intravenous RLF-100 improves survival, oxygenation, and clinical course of Critical COVID-19 with respiratory failure. The independent Data Monitoring Committee of that trial has conducted the first unblinded look at the study data and identified no safety signals. Moreover, the DMC has determined that the study is not futile in its objective to identify a statistically significant difference between aviptadil and placebo in remission from COVID-19 respiratory failure.